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Enzymes from natural product biosynthetic path-
ways are attractive candidates for creating tailored
biocatalysts to produce semisynthetic pharmaceu-
tical compounds. LovD is an acyltransferase that
converts the inactive monacolin J acid (MJA) into
the cholesterol-lowering lovastatin. LovD can also
synthesize the blockbuster drug simvastatin using
MJA and a synthetic a-dimethylbutyryl thioester,
albeit with suboptimal properties as a biocatalyst.
Herewe used directed evolution to improve the prop-
erties of LovD toward semisynthesis of simvastatin.
Mutants with improved catalytic efficiency, solubility,
and thermal stability were obtained, with the best
mutant displaying an11-fold increase in an Escher-
ichia coli-based biocatalytic platform. To understand
the structural basis of LovD enzymology, seven X-ray
crystal structures were determined, including the
parent LovD, an improved mutant G5, and G5 coc-
rystallized with ligands. Comparisons between the
structures reveal that beneficial mutations stabilize
the structure of G5 in a more compact conformation
that is favorable for catalysis.
INTRODUCTION
Tailoring enzymes found in natural product biosynthetic path-
ways catalyze a wide array of reactions, including acyltransfer
(Loncaric et al., 2006), glycosylation (Zhang et al., 2006), hydrox-
ylation (Rix et al., 2002), and halogenation (Neumann et al.,
2008). A number of these enzymes decorate biologically inactive
precursors into pharmaceutically active molecules via regiose-
lective and stereoselective transformations. As a result, tailoring
enzymes are attractive candidates as biocatalysts toward syn-
thesis of semisynthetic derivatives and drug libraries (Zhou
et al., 2008). LovD is an acyltransferase found in Aspergillus
terreus and is responsible for converting the inactive precursor
monacolin J acid (MJA) into the cholesterol-lowering drug lova-
statin (LV, acid form lovastatin acid: LVA) via acylation of the a-S-
methylbutyrate side chain (Kennedy et al., 1999; Xie et al., 2006)
(Figure 1). The importance of the hydrophobic a-S-methylbutyryl1064 Chemistry & Biology 16, 1064–1074, October 30, 2009 ª2009 Eside chain for binding of LVA to HMG-CoA reductase has been
structurally confirmed (Istvan and Deisenhofer, 2001). Chemical
modification of the LV side chain to a-dimethylbutyrate yielded
the semisynthetic derivative simvastatin (SV, acid form simvas-
tatin acid: SVA), which is the active pharmaceutical ingredient
in the blockbuster drug Zocor (Hoffman et al., 1986). Semisyn-
thesis of SV from LV is a multiple-step chemical process and is
therefore an intensely pursued target for devising an efficient
biocatalytic approach (Berg et al., 2009; Morgan et al., 2006). As
a result, LovD is a prime candidate to serve as such a biocatalyst.
LovD is a 413 amino acid protein predicted to have an
a/b hydrolase fold based on primary sequence analysis (Ken-
nedy et al., 1999). Among enzymes of known structure that are
homologous to LovD is cephalosporin esterase, EstB (PDB ID
1CI9, 26% sequence identity) fromBurkholderia gladioli (Wagner
et al., 2002). The likely general base Tyr188, as well as a
conserved SXXK patch that contains the active site nucleophile
Ser76, were indicated through alignment of LovD with EstB
(Figure 2A) (Petersen et al., 2001). During LVA biosynthesis, the
a-S-methylbutyrate side chain is synthesized by the lovastatin
diketide synthase (LDKS) LovF, and is then transferred by
LovD regioselectively to the C8 hydroxyl of MJA via an unprece-
dented polyketide offloading mechanism (Xie et al., 2009a). The
protein-protein interaction between LovD and the acyl carrier
protein (ACP) domain of LovF facilitates this highly efficient
tailoring reaction in A. terreus. We have previously explored the
substrate promiscuity of LovD and have shown that it can also
synthesize SVA by using the small molecule substrate a-dime-
thylbutyryl-S-methyl-mercaptoproprionate (DMB-SMMP) as an
acyl donor (Xie and Tang, 2007) (Figure 1). Using Escherichia
coli as an expression host, a whole-cell biocatalytic platform
for converting MJA to SVA was established that can produce
SVA with low throughput (Xie and Tang, 2007). However, as
with many enzymes that have been removed from their natural
context, LovD is catalytically suboptimal as a biocatalyst and
suffers from poor thermal stability (Arnold, 2001). The catalytic
activity of SVA synthesis using DMB-SMMP is attenuated
1300-fold when compared with the natural substrate attached
to LovF (Xie et al., 2009a), indicating there is ample opportunity
for optimization by protein engineering efforts. Furthermore,
the structural basis of LovD function and substrate selection
had not been elucidated, limiting our ability to rationally optimize
the binding of the unnatural dimethylbutyryl substrate and
improve LovD efficiency as a SV synthase.lsevier Ltd All rights reserved
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Directed Evolution and Structure of LovDIn this article, we employed directed protein evolution
(Arnold and Volkov, 1999) to improve the SV synthase activity
of LovD. After seven rounds of screening, LovD mutants with
significantly improved catalytic activities and higher thermal
stability were isolated. In parallel, seven X-ray crystal structures
including the parent LovD G0, an improved mutant G5, and
the cocrystal structures of G5 with MJA, LVA, and SVA were
obtained. The crystal structures provide atomic-resolution
Figure 1. Reactions Catalyzed by LovD
LovD is responsible for converting MJA into LVA via acylation of the a-S-methylbutyrate side chain and can also synthesize SVA using DMB-SMMP as an acyl
donor.
Figure 2. The Crystal Structure of LovD and
its Relationship to EstB
(A) A structure-based sequence alignment
between LovD and EstB. Secondary structure
elements assigned from the structure of LovD
are shown above the sequence. The colors are
ramped from blue at the N terminus to red at the
C terminus. The active site residues in EstB are
indicated by an asterisk ‘‘*’’ below the amino acid.
(B) A stereo ribbon diagram showing the G50-LVA
complex.
(C) Structure of LovD. Highlighted in green are
segments that are not conserved in EstB. These
five loops project around the circumference of
the active site like the fingers in a catcher’s mitt.
(D) Structure of EstB. Highlighted in magenta are
segments that are not conserved in LovD.
(E) The overlay of LovD and EstB structures.
Notably absent from LovD is a loop that covers
the active site in EstB (residues 244–260).Chemistry & Biology 16, 1064–1074, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1065
Chemistry & Biology
Directed Evolution and Structure of LovDFigure 3. Directed Evolution of LovD as a Simvastatin Synthase
(A) An agar diffusion-based assay was used to quantify the amount of SVA in the whole-cell activity experiments. N. crassa was embedded in the agar prior to
spotting the reaction mixture. The numbers (1–8) designate different incubation times of 2.5, 4, 5.5, 7, 8, 9, 10, and 12 hr following addition of MJA and DMB-
SMMP to E. coli expressing wild-type LovD.
(B) Directed evolution of LovDmutants toward higher whole-cell activities. There are a total of seven generations of LovDmutants. Four generations were derived
from random mutagenesis including G1, G2.1, G2.2, G4.1, G4.2, and G6. Two generations were derived from combination of beneficial mutations from previous
generation mutants including G3 and G5. G7 was derived though saturated mutagenesis of G6 at positions V334 and L361. All mutants with two amino acid
changes were subjected to site-directed mutagenesis to determine beneficial or deleterious mutations (G2.1, G4.1, and G4.2). (3) indicates that the mutant
had lower whole-cell activity compared with the previous generation. (O) indicates that the mutant had higher whole-cell activity compared with the previous
generation.details regarding the mechanism of catalysis, substrate and
product binding, protein-protein interactions with LovF, and
a likely explanation for the effects of beneficial mutations on
catalysis.
RESULTS
Development of an Agar-Based Diffusion Screening
Method
We developed an efficient screening method to assay for E. coli
expressing LovD mutants with improved properties in the
synthesis of SVA from MJA and DMB-SMMP. The assay relied
on the growth inhibition of Neurospora crassa by statins, a prop-
erty that was previously exploited in the screening of high LV
producing A. terreus strains (Kumar et al., 2000). We found that
SVA can inhibit the growth of N. crassa at submicrogram quan-
tities, whereas inhibition by MJA requires hundred milligram
quantities. To demonstrate the sensitivity and feasibility of the
assay, an E. coli culture expressing wild-type LovDwas supplied
with 10 mM MJA and 15 mM DMB-SMMP. At different time
points, 2 ml aliquots were directly spotted on a Sabouraud’s
dextrose agar (SDA) plate embedded with N. crassa at a density
of 0.30.5 3 108 spores/l. After 16 hr of incubation at 30C,
different inhibition zones were observed for samples containing
different degrees of conversion from MJA to SVA (as verified
by high-performance liquid chromatography [HPLC]) (Figure 3A).
Based on this screening strategy, any significant contribution
to whole-cell LovD activity (defined as the rate of converting
MJA to SVA by E. coli cultures expressing LovD variants; see
Experimental Procedures), such as improvements in solubility,
catalytic efficiency and stability, can lead to a detectable pheno-
typical change.1066 Chemistry & Biology 16, 1064–1074, October 30, 2009 ª2009Screening of LovD Variants with Enhanced Whole-Cell
Activities
The starting LovD (generation zero or G0) used in directed evolu-
tion is the previously generated double mutant C40A/C60N from
wild-type LovD (Xie et al., 2009b). G0 was rationally engineered
to be less prone to disulfide-mediated aggregation andwas used
for crystallization studies (Xie et al., 2009b). The mutant libraries
were created by either saturation mutagenesis or error-prone
polymerase chain reaction (ep-PCR) that generated an average
of 2.5 amino acid changes per round (Fromant et al., 1995).
During each round of screening, the mutant library was ligated
into pET28(a) and electroplated into YT2 competent cells (Xie
et al., 2007). The individual mutants were cultured in 96-well
plates, followed by induction of LovD expression, addition of
MJA and DMB-SMMP, and spotting onto N. crassa embedded
plates. Table 1 shows the gradual improvement in whole-cell
activity obtained following four rounds of ep-PCR (G1, G2, G4,
G6), one round of saturatedmutagenesis (G7), and two iterations
of combining individual beneficial mutations (G3, G5), with the
best mutant G7 displaying 11-fold increase in whole-cell
activity as a SV synthase compared with G0 (Figure 3B). The
mutant G2.1 contains amino acid changes at D12G and
G275S. Construction of the corresponding single mutants using
G1 as template showed that D12G alone had a large negative
effect, whereas G275S alone had a weak positive effect
compared with G1. This result suggests the two mutations in
G2.1 act synergistically to enhance LovD activities. Combination
of mutations from G2.1 and the A190T mutation in G2.2, which
was recovered from the same round of ep-PCR, yielded the
next-generation mutant G3. Ep-PCR using G3 as a template
yielded G4.1 and G4.2, each containing a different double muta-
tion combination of A10V/K26E and H161Y/K227R, respectively.Elsevier Ltd All rights reserved
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Mutations
Whole-Cell
Activitya kcat (min
1) KM of MJA (mM)
b
KM of DMB-
SMMP (mM1)c
Soluble
Protein (mg/l)d Tm(
C)e
G0 1 0.66 ± 0.03 0.77 ± 0.17 0.67 ± 0.12 138 ± 11 39.5 ± 0.4
G1 A86V 1.2 0.79 ± 0.03 0.74 ± 0.16 0.66 ± 0.19 140 ± 5.4 41 ± 0.7
G2.1 A86V D12G G275S 1.9 1.14 ± 0.03 0.91 ± 0.17 0.62 ± 0.10 184 ± 8.7 40.5 ± 0.4
G2.2 A86V A190T 1.8 1.20 ± 0.09 0.74 ± 0.21 0.69 ± 0.17 168 ± 17 41 ± 0.4
G3 A86V D12G A190T G275S 3.6 1.86 ± 0.09 0.77 ± 0.11 0.70 ± 0.19 205 ± 23 41 ± 0.4
G4.1 A86V D12G A190T
G275S A10V K26E
4.8 2.13 ± 0.03 0.70 ± 0.24 0.66 ± 0.16 183 ± 18 43.5 ± 0.7
G4.2 A86V D12G A190T
G275S H161Y K227R
5.2 2.16 ± 0.12 0.80 ± 0.24 0.64 ± 0.16 221 ± 9.3 42.5 ± 1.9
G5 A86V D12G A190T
G275S K26E H161Y
6.4 2.61 ± 0.03 0.74 ± 0.03 0.69 ± 0.14 206 ± 5.7 46.5 ± 0.4
G6 A86V D12G A190T G275S
K26E H161Y V334D L361M
9.3 3.30 ± 0.06 0.70 ± 0.07 0.63 ± 0.15 212 ± 3.9 47 ± 0.1
G7 A86V D12G A190T G275S
K26E H161Y V334F
11.2 4.80 ± 0.06 0.70 ± 0.04 0.69 ± 0.17 214 ± 6.3 48.5 ± 0.7
a The whole-cell activity of LovD mutants are compared with G0, which has a conversion rate of 1.7 mM/hr and is normalized to 1.
bKM of MJA is derived at 25
C when DMB-SMMP is fixed at 2 mM.
cKM of DMB-SMMP is derived when MJA is fixed at 2 mM.
d The amounts of soluble proteins are measured from purified protein levels.
e Tm is measure by circular dichroism. All results represent mean values of triplicate determinations and standard deviations.Site-directed mutagenesis confirmed that both A10V and K227R
had negative effects on the activities of LovD. Removal of these
mutations and combination of K26E and H161Y yielded an
improved mutant G5, which was 6-fold improved in whole-
cell activity compared with G0. At this point, structural studies
were performed on the G5 mutant to provide insights into the
accumulated beneficial mutations. In parallel, an additional
round of ep-PCR affordedG6 that contained the beneficial muta-
tions V334D and L361M. Saturation mutagenesis was employed
to optimize the combined effects of mutations at positions 334
and 361. The best mutant recovered was G7, of which the
whole-cell activity was increased an additional 20%. Surpris-
ingly, we found that while position 334 was altered to phenylala-
nine, the previously deemed beneficial L361Mmutation reverted
back to leucine. Site-directed mutation of L361M in G7
confirmed that leucine was indeed the more favorable residue
in the context of the V334F mutation.
In Vitro Characterization of LovD Variants
To dissect the contributions that led to the increases in whole-
cell activity, kinetic parameters (kcat, KM), soluble protein levels
and thermal stability of all the improved mutants were charac-
terized and listed in Table 1. The binding affinities (KM) of
LovD mutants toward MJA and DMB-SMMP were each within
a narrow range (0.7 mM to 0.9 mM for MJA and 0.6 mM to
0.7 mM for DMB-SMMP). The lack of improvement in KM
toward either substrate is not surprising considering the high
concentrations of substrates used in the screening assay
(10 KM of MJA and DMB-SMMP). The observed improvements
in whole-cell activity are mainly due to increases in the kcat of
the mutants and levels of soluble proteins. The kcat and
soluble protein levels were simultaneously increased 3-fold
and 1.5-fold from G1 to G3, respectively. Impressively, theChemistry & Biology 16, 1064–1protein expression levels of G3 reached 205 mg/l. In contrast,
improvements in kcat were the sole contribution to the increases
in whole-cell activities from round 4 to round 7. Most notably,
a single V334F mutation from G5 to G7 nearly doubled the cata-
lytic turnover rate. We also observed a gradual increase in the
melting temperature (Tm) of the LovD mutants from 39.5
C to
48.5C by using circular dichroism. The increases in thermal
stability were also reflected in the whole-cell activities of the
mutants when expressed at elevated temperatures (see
Figure S1 available online). Whereas the G0–G3 mutants have
no detectable activity when expressed at 32C, the later gener-
ation mutants retained significant SV synthase activities, with
the G7 mutant exhibiting comparable activity to that of G0 at
25C. Furthermore, the G7 mutant remained active even when
expressed at 37C. The increased thermal stabilities of the
mutants have important practical implications in using LovD
as a biocatalyst for SV semisynthesis.
To examine the activities of the mutants toward synthesis of
the natural biological product LVA, we performed kinetic assays
using a-methylbutyryl-SMMP (MB-SMMP) and MJA. A similar
trend in the improvements of kcat toward LVA synthesis was
observed (Figure S2), indicating the LovD relative substrate
specificity toward the acyl group (either MB or DMB) has not
changed. Interestingly, when LovF was used in the kinetic assay
for LVA synthesis (Figure 1), we observed a progressive loss of
activities of the LovD mutants (Figure S2). The G7 mutant
exhibited a 27-fold decrease in activities toward LovF compared
with the G0 parent, most likely attributed to the deterioration of
the required protein-protein interactions for catalysis (Xie et al.,
2009a). Therefore, the mutations accumulated during directed
evolution might have gradually altered the conformation of
LovD to impair its communication with LovF, while not affecting
binding of the SMMP-bound acyl group.074, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1067
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Seven LovD crystal structures were determined to help illumi-
nate the mechanism of the LovD-catalyzed reaction and
possible basis for improved catalysis. These include (1) G0, (2)
selenomethionyl G0 (G0-Semet), (3) the improved mutant G5,
(4) G5 in complex with substrate MJA, the G5 with S76A active
site mutated (called G50) in complex with (5) LVA, (6) SVA, and
(7) MJA. The resolution limits of the structures range from
2.5 to 2.0 A˚ except for G0. The native G0 structure was resolved
at 3.4 A˚, but was improved to 2.5 A˚ in the G0-Semet variant.
Refinement statistics are provided in Table 2.
The crystal structure of LovD G0-Semet revealed a variation
of the a/b hydrolase fold (Heikinheimo et al., 1999; Nardini and
Dijkstra, 1999). It consists of two domains. The first domain (resi-
dues 1–92 and 204–413) is a central seven-stranded antiparallel
b sheet flanked by a helices on either face (Figures 2B and S3A).
A cis-peptide bond is formed between Glu388 and Pro389,
contributing to a kink in the sheet. The second domain is smaller
(residues 93–203) and primarily a-helical. A deep and narrow
cleft (11 3 6 A˚) is formed at the interface between the two
domains. At the bottom of the cleft is the catalytic Ser76 that
acts as the nucleophile in the acyltransfer reaction.
Comparison between LovD and EstB
Encircling the active site cleft is a broad, ring-shaped ridge,
which is absent from the homologous enzyme EstB. Their struc-
tures are superimposable with root-mean-square deviation
(rmsd) of only 1.5 A˚ over 270 pairs of a-carbons (about two-thirds
of the structure) (Figure 2E). The similarity is striking for the core
of the two enzymes, but they differ notably in the loops peripheral
to the active site, both in size and architecture. In LovD, these
loops give the impression of a ring-shaped ridge or baseball
catcher’s mitt over the active site with fingers composed of
five loops: residues 114–125, 147–173, 243–258, 321–327, and
388–391 (Figure 2C). The first and last of these loops are longer
in LovD than in EstB by 11 and 19 residues, respectively. The
second loop is displaced 7 A˚ from the active site compared
with EstB, extending the grasp of the ‘‘mitt.’’ Most notably
absent from the LovD molecule is the 23-residue loop that if
present would obstruct the grasp of the mitt and cover the active
site entrance (corresponding to residues 244–260 in EstB)
(Figure 2D). The shape and diameter of the ridge surrounding the
active site (a circle of 17 A˚ diameter) satisfies the requirement of
accommodating LovD’s natural binding partner, the ACP of LovF
(Xie et al., 2009a). The distance between the rim of LovD and
active site Ser76 is 20 A˚, which is roughly the same as the
length of the phosphopantetheine (Ppant) arm of the ACP
domain of LovF.
Crystal Structures of the Mutant G5
The LovD G0-Semet structure enables us to identify residues
important for catalytic efficiency, which, when mutated to LovD
G5, improved the kcat 4-fold. These residues are scattered
widely over space, forming nomutual contacts. Further, because
they are located in both buried and solvent exposed regions,
they do not share a common physical environment. Moreover,
distances of these residues to the active site Ser76 are relatively
large, ranging from 10 to 32 A˚ for Thr190 and Gly12, respectively
(Figure 4). The lack of connectivity of the residues to each other1068 Chemistry & Biology 16, 1064–1074, October 30, 2009 ª2009and to the active site is a common phenomenon in numerous
directed evolution experiments (Hsu et al., 2005; Oue et al.,
1999; Zhao and Arnold, 1999).
The crystal structure of G5, however, offered evidence to
suggest that the increased activity afforded by its six mutations
can be attributed to their ability to stabilize amore closed form of
the active site cleft. Comparison of the G0-Semet structure with
G5 revealed a rotation about the domain-domain hinge of 5,
narrowing the cleft by about 0.5 A˚ and producing motions up
to 3 A˚ for atoms furthest from the hinge (Figure 5A). Subsequent
structures of G50 bound to the LVA showed larger movements
along the same trajectory arising from a 14 hinge rotation.
That observation suggests that the beneficial mutations in the
G5 variant help promote a conformational change required for
catalysis.
Stabilization of the closed conformation of LovD might
enhance activity by positioning residues critical for catalysis.
For example, when the large domains of G0-Semet, G5, and
G5-MJA are superimposed (residues 14–92 and 204–405),
domain rotation from G0-Semet to G5 closes the gap between
the guanido group of Arg173 and the C15 carboxylate of MJA
by 0.5 A˚ . This rotation could be attributed to the G5 mutations
(and perhaps to a difference in crystal packing) but not to ligand
binding, since the comparison is between two unliganded struc-
tures. Ligand binding produces a further rotation from G5 to
G5-MJA, which closes the gap between Arg173 and MJA
by an additional 2.2 A˚, so that a hydrogen bond is formed
between the two groups. Similarly, G5 mutations bring Phe148
and Tyr188 side chains from the G0-Semet position closer to
substrate (G5-MJA), although their motion is smaller because
they lie closer to the hinge axis (Figure S4A).
The A86V mutation in particular appears responsible for
stabilizing closure of the hinge. Its two additional methyl groups
buried in the boundary between domains act as a wedge
pushing against Leu134 on the distal side of the hinge axis,
thereby closing the active site cleft on the proximal side of the
hinge axis (Figure 5A). The beneficial effects of the K26E and
G275S mutations are less obvious. The K26E mutation might
improve stability of the enzyme by breaking up a patch of posi-
tively charged residues (R22, K23, K26, and R28) on the surface
of helix A (Figure S5A) (Schweiker et al., 2007). The G275Smuta-
tion appears to improve stability of the enzyme by adding a
hydrogen bond with the N-terminal end of helix I and decreasing
torsional flexibility of the backbone (Figure S5B).
Cocrystallization of LovD G50 with MJA, LVA, and SVA
Structures of LovD G50 in complex with substrate and products
illustrate the mode of binding of these ligands and suggest
a catalytic mechanism for acyl transfer. The substrate MJA binds
with its C8-hydroxyl group deep inside the cleft between
domains, forming hydrogen bonds with Ser76, Tyr188, and
a fortuitously bound formatemolecule (used as a cryoprotectant)
(Figure 6A). The proximity of the C8-hydroxyl to the Ser76
hydroxyl is consistent with the expectation that both hydroxyl
groups initiate a nucleophilic attack on the same acyl group
during different steps in the reaction sequence (Figure S6B).
The two faces of the decalin ring system of MJA are sandwiched
between the aromatic rings of Trp390 and Tyr188 (Figure S3C).
Additional hydrophobic and van der Waals interactions withElsevier Ltd All rights reserved
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Tyr327, Phe148, Leu149, and the peptide planes of Gly364,
Gly365, and Gly366 (Figure S3C). The hydrophilic tail of MJA
(i.e., the C1 substituent on the decalin ring) extends away from
the active site into bulk solvent. The C11 hydroxyl group
hydrogen bonds with the Glu388 side chain and the backbone
Table 2. Statistics of X-ray Data Collection and Atomic Refinement
Protein G0 SeMet G0 G5 G5 G50 G50 G50
Ligand None None None MJA MJA SVA LVA
Data collection
Space group P1 C2 P212121 P212121 P212121 P212121 P212121
Cell dimensions
a, b, c (A˚) 56.7,79.7,104.1 209.5,85.2,104.0 58.2, 75.0, 131.6 58.5, 75.2, 133.5 58.0, 75.2, 132.7 58.5, 75.1, 131.8 59.0, 75.2, 131.7
a, b, g () 94.1,91.6,106.8 90.0,117.5,90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Protomers/
asymmetric unit
4 4 1 1 1 1 1
Resolution (A˚) 100.00-3.40 80.00-2.50 90.00-2.00 60.00-2.00 60.00-2.05 60.00-2.00 60.00-2.00
(3.66-3.40) (2.59-2.50) (2.07-2.00) (2.07-2.00) (2.12-2.05) (2.07-2.00) (2.07-2.00)
Rmerge (%) 20.8 (43.4) 11.8 (45.3) 4.9 (37.8) 15.6 (39.6) 6.8 (40.2) 6.9 (31.4) 11.8 (39.6)
I / sI 5.1 (2.9) 10.2 (1.7) 47.2 (6.5) 13.0 (4.8) 38.3 (6.6) 19.5 (3.9) 13.33(4.64)
Completeness (%) 99.3(98.9) 89.9 (46.7) 99.9 (100.0) 99.8 (100.0) 99.9 (99.8) 97.7 (99.6) 98.5 (99.5)
Redundancy 3.7(3.7) 5.3 (3.0) 11.6 (11.7) 6.2 (6.4) 15.4 (12.9) 4.9(4.9) 6.4(6.5)
Wavelength (A˚) 0.9793 0.9793 0.9794 0.9794 0.9792 &1.5418 0.9717 0.9795
Refinement
Resolution (A˚) 103.7- 3.4 65.9- 2.50 65.80- 2.00 46.18- 2.00 49.86- 2.05 49.51- 2.00 46.42- 2.00
(2.06- 2.00)(3.5- 3.4) (2.56- 2.50) (2.05- 2.00) (2.05- 2.00) (2.10- 2.05) (2.05- 2.00)
No. reflections 22457 (1669) 47728 (1657) 37539 (2837) 38325 (2910) 35223 (2686) 36938 (2714) 37005 (2671)
Rwork / Rfree (%) 23.1/27.5
(31.9/35.5)
24.8/29.0
(35.6/40.5)
17.9/20.6
(20.4/24.4)
17.9/21.3
(21.5/26.1)
17.7/20.9
(19.8/23.7)
17.6/20.9
(23.1/25.1)
16.2/18.9
(18.3/21.8)
Number of atoms
Protein 12328 12547 3289 3332 3355 3351 3343
Ligand/ion 1 0 65 (sulfate) 13 (PEG) 48 (MJA) 24 (MJA) 31(SVA) 30
Ligand/ion 2 0 0 6 (glycerol) 12 (formate) 8 (dithiothreitol) 0 0
Water 0 21 151 275 157 179 230
B-factors (A˚2)
Protein 6.3 51.7 34.4 27.6 35.4 32.2 31.4
Ligand/ion 1 n/a 68.0 (SO4) 58.6 (PEG) 58.8 (MJA) 46.5 (MJA) 45.5 (SVA) 38.3 (LVA)
Ligand/ion 2 n/a n/a 58.2 (glycerol) 38.6 (formate) 74.2
(dithiothreitol)
n/a n/a
Water n/a 39.4 36.9 32.8 37.6 36.1 37.2
Rmsds
Bond lengths (A˚) 0.011 0.006 0.009 0.009 0.008 0.008 0.008
Bond angles () 1.3 0.995 1.199 1.230 1.202 1.193 1.193
Ramachandran
Plot (%)
Most favored 88.0 90.0 91.2 89.4 89.7 90.3 90.6
Additionally
allowed
11.4 9.7 8.5 10.3 10.0 9.4 9.1
Generously
allowed
0.6 0.3 0.3 0.3 0.3 0.3 0.3
Disallowed 0.0 0.0 0.0 0.0 0.0 0.0 0.0
PDB ID code 3HL9 3HLB 3HLC 3HLD 3HLE 3HLF 3HLG
Rmerge = SjI < I > j2/SI2, where I is the observed intensity. Both summations involve all input reflections for which more than one symmetry equivalent
is averaged. Rwork = SkFoj  jFck/SjFoj, where Fo and Fc refer to observed and calculated structure factors, respectively. Rfree is similar to Rwork, but is
based on a subset of the reflections, which were withheld from refinement for cross validation. Numbers in parentheses refer to the outer shell of data.Chemistry & Biology 16, 1064–1074, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1069
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The C15 carboxylic acid forms a salt bridge with Arg173.
The position of the a-S-methylbutyryl group is revealed in the
crystal structure of the LovD G50 mutant in complex with LVA. As
in the MJA complex, the decalin ring and hydrophilic tail of LVA
bind with similar geometry. Interestingly, the additional methyl-
butyryl group extends parallel to the MJA hydrophilic tail
(Figure 6B). The proximity of the two tails gives LVA a hairpin
shape, with the decalin ring forming the hairpin turn between
the two tails. The hydrophobic side-chain binding position is
likely the site at which the acyl donor binds. The proximity of
the tails also suggests how MJA competitively inhibits the acyl
transfer reaction when it binds prior to the methylbutyryl
substrate (Xie et al., 2006), because the hydrophilic tail of MJA
partly obstructs access of the methylbutyryl group to the active
site, ordered binding of the substrates is required.
Structural comparisons between complexes of LovD G50 with
LVA and SVA suggest some strain is involved in accommodating
the nonnatural product, SVA (Figure 6C). SVA contains an addi-
tional methyl group compared with LVA, located on the a-S-
methylbutyryl moiety. Superimposition using only a carbons in
Figure 4. Structure of the G5 Mutant Provides Insight into Improved
Catalysis
Positions of the amino acid changes present in the improved mutant G5, high-
lighting their generally large distances from the active site. Distances are
drawn from the amino acid a carbons to the nucleophilic hydroxyl (C8) of
LVA (shown in green).1070 Chemistry & Biology 16, 1064–1074, October 30, 2009 ª2009 Ethe large domains of the two structures shows nearly identical
arrangements of atoms in the large domains and the decalin
rings (Figure 6D). But contact between the additional methyl
group (attached at C20) and the side chain of Phe148 appears
to push open the cleft between domains. As a result, Phe148
moves approximately 0.8 A˚ away from its position in the LVA
complex (Figure S4B). There is also a 30 rotation about the
C10-C20 bond of the a-dimethylbutyryl moiety. The consequence
of these rotations for the relative catalytic rates of the two
substrates appears minor; the movements near the atoms
directly involved in acyl transfer are small. This is consistent
with the ability of LovD to catalyze acyl transfer using an a-dime-
thylbutyryl group as substrate instead of the natural a-methyl-
butyryl group. However, further amino acid mutations, such as
the aforementioned Phe148, could improve the fit to the a-dime-
thylbutyryl substrate, or other variations. The structures pre-
sented here provide a framework for such design efforts.
DISCUSSION
In this work, we show that seven amino acid changes led to the
11-fold increase in the SV synthase activity of LovD. This level
of enhancement is significant considering G0 was already an
adequate SV synthase following our previous efforts in substrate
and strain optimization. Although the kinetic activity of G7 is far
below that of the natural reaction catalyzed by LovD using
acyl-LovF, G7 is a robust mutant for high-volume synthesis of
SVA using the whole-cell platform. When G7 was applied in
a high-density fermentation environment, more than 30 g/l
MJA was quantitatively converted to SVA within 1 day. The rela-
tively few rounds of direct evolution to achieve the activities of G7
also demonstrate that LovD is highly evolvable as a biocatalyst.
The X-ray crystal structures solved in this work provides
insight into different facets of LovD enzymology. Among these,
the spatial arrangement of the LovD catalytic triad Ser76-
Lys79-Tyr188 was captured and is shown to be consistent
with that of the esterase EstB (Figure S6). Tyr188 (as the pheno-
late) appears to be the general base in initiating the two nucleo-
philic attacks required for completion of the acyl transfer reaction
(Oefner et al., 1990). The first nucleophilic attack is by Ser76 on
the a-S-methylbutyryl group and the second attack is by the C8
hydroxyl of MJA on the acylated enzyme intermediate. In both
reactions, the attacking hydroxyl group must be activated by
deprotonation (Figure S6C). Tyr188 is well-positioned to deprot-
onate both hydroxyl groups, forming hydrogen bonds with Ser76
in the apo-enzyme and with MJA in the G5-MJA complex. Lys79
is also well-positioned to aid in activating the two hydroxyl
groups by forming a hydrogen bond relay with Tyr188 in the
G5-MJA complex. Site-directed mutation of either Tyr188 or
Lys79 to alanine resulted in complete loss of activity.
Details of the a-S-methylbutyryl binding pocket suggest how
the transition states for the acyl transfer reactions are stabilized.
As in the MJA complex, the C8 oxygen of LVA maintains
a hydrogen bond to Tyr188, but the neighboring water molecule
has been displaced by the carbonyl oxygen of the a-S-methylbu-
tyryl group. This carbonyl oxygen forms a pair of hydrogen bonds
with the backbone amides of Ala76 (i.e., Ser76 in the G0-Semet)
and Gly366. The geometry of the hydrogen bonds appears ideal,
with the amide hydrogen atoms pointed directly at the two lonelsevier Ltd All rights reserved
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Directed Evolution and Structure of LovDFigure 5. Side View of the Overlap of Five LovD Structures
This representation indicates a hinge rotation between two domains due to G5 mutations and the presence of bound ligands.
(A) Two important residues (Val86 and Leu134), which may stabilize closure of the hinge, are shown in spheres.
(B) Another two residues (Val334 and Asp320) are directly in contact with each other. Mutation V334D in G6 would result in electrostatic repulsion between
Asp334 and Asp320, while mutation V334F in G7 could result in steric clash between the phenyl side chain and Asp320. Both could stabilize closure of the hinge.electron pairs on the carbonyl oxygen. These hydrogen bonds
would appear well suited to stabilize a tetrahedral transition
state. The closest protein contacts with the aliphatic portion of
the methylbutyryl group are aliphatic or aromatic carbons:
Ala75 (Cb), Phe148 (Cz), Tyr146 (Cz), and Asn270 (Cb). Notably,
the a-S-methylbutyryl aliphatic carbons are also surrounded
by three positively charged side chains, Arg73, Lys79, and
Arg173, all within 4.1 A˚. These positive charges might help stabi-
lize the negative charge of the oxyanion hole that forms during
acyl transfer. Indeed, the pocket’s affinity for negative charges
is demonstrated by the fortuitous presence of a bound formate
anion in this position in the G5-MJA complex.
The crystal structures provide plausible explanations for the
basis of enhanced catalytic efficiency. Upon ligand binding,
LovD undergoes a conformational change analogous to the
closing of the catcher’s mitt. Movement of the domains shown
in Figure 5A positions the catalytic residues in closer proximity
to each other and to the ligands, and serves to enhance the
rate of catalysis. The G5 structure suggested that beneficial
mutations afforded an alternative way to pre-position the active
site residues to increase the catalytic efficiency. Although the
V334D and V334F mutations of G6 and G7, respectively, were
discovered subsequent to the structural work of G5, the molec-
ular explanation above can also be applied to rationalize the
beneficial nature of the additional single mutations. Val334 is
located in the middle of a loop between helix K and sheet 12.
The two side-chain methyl groups of Val334 are directly in
contact with the side chain of Asp320 on helix K, which serves
as one of the domain-domain hinges and is in contact with the
loop where Tyr188 is located (Figure 5B). Mutation of V334 could
therefore result in movement of the domains around the helix KChemistry & Biology 16, 1064–hinge. For example, the mutation V334D in G6 would result in
electrostatic repulsion between Asp334 and Asp320. Similarly,
the mutation V334F in G7 could result in steric clash between
the phenyl side chain and the side chain of Asp320, further
closing the active site cleft and bringing key residues (e.g.,
Tyr188) into more optimal positions for catalysis. On the other
hand, the more compact conformations of LovD mutants are
less compatible with binding to LovF, which apparently favors
the open conformation of LovD.
SIGNIFICANCE
SV is the active pharmaceutical ingredient of the block-
buster cholesterol-lowering drug Zocor. Semisynthesis
of SV from LV is therefore an intensely pursued target for
devising an efficient biocatalytic approach. Our previously
developed platform for the biosynthesis of SV was powerful,
but still suboptimal due to the lack of a robust biocatalyst.
In this work, we employed directed evolution to engineer
LovD. Several better mutants were obtained and the best
mutant ‘‘G7’’ displayed an 11-fold increase in whole-cell
biosynthesis of SVA compared with the parent G0. Catalytic
efficiency, solubility, and thermostability were improved
simultaneously. We have determined seven X-ray crystal
structures including the parent LovD G0, an improved
mutant G5, and the cocrystal structures of G50 with MJA,
LVA, and SVA. The structure information not only aided our
understanding of the catalytic mechanism of LovD, but
also afforded insights into howmutations affected the over-
all properties of LovD. Comparing the structures between
LovD G0 and G5 suggests the beneficial mutations help1074, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1071
Chemistry & Biology
Directed Evolution and Structure of LovDFigure 6. Comparison of the LovD Active Site Bound with Different Ligands
(A) G5 in complex with substrate MJA.
(B) G50 in complex with product LVA.
(C) G50 in complex with product SVA.
(D) Overlay of the three structures showing conformational changes, particularly at the nucleophilic serine, associated with binding to different ligands. Dashed
lines represent hydrogen bonds. The active site entrance is at the top of each figure. Some residues involved in ligand binding are not shown.promote a more compact conformation required for catal-
ysis. The cocrystallization of LovD G50 with substrate MJA,
product LVA and SVA reveals how acyl transfer reaction
proceeds via a ping-pong mechanism, how MJA becomes
a competitive inhibitor, and how the catalytic cavity is adap-
ted to accommodate its nonnatural product. Our work,
therefore, can have significant impact on biocatalyst devel-
opment and provides insights into fundamental under-
standing of enzymology.
EXPERIMENTAL PROCEDURES
Ep-PCR and Construction of Mutant Library
Ep-PCR procedure was modified from established protocols (Fromant et al.,
1995). The reaction consisted of 0.35 mM dATP, 0.4 mM dCTP, 0.2 mM
dGTP, 1.35 mM dTTP, 4 mM MgCl2, 0.25 mM MnCl2, and 2.5 U Taq poly-
merase. The reaction mixture was submitted to 25 cycles of PCR: 94C for
1 min, 55C for 1 min, and 72C for 3 min. The resulting PCR products were
digested with DpnI, further digested with EcoRI and NdeI, and ligated to
pET28(a). The ligation mixture was transformed to YT2 and plated on LB
agar containing 35 mg/l kanamycin.
Selection of High Activity Mutants
N. crassa was grown on SDA slants for 10 days and spores were harvested
with 1% Tween-80. Then 100 ml molten SDA was seeded with 0.3–0.5 3
108 spores and poured into a 230 3 230 mm plate. Colonies from mutation
library were cultured in 96 well plates containing 250 ml LB medium (with
35 mg/l kanamycin). The cells were grown at 37C to saturation and trans-1072 Chemistry & Biology 16, 1064–1074, October 30, 2009 ª2009 Eferred to duplicated plates. Protein expression was induced with 0.1 mM
IPTG at OD600 of 0.5 and the expression was performed at 25
C for 16 hr.
Then 5 mM MJA and 10 mM DMB-SMMP were added to initiate the reaction.
After a certain reaction time (45 min to 4 hr depending on the activity of
the parent), cells were removed with centrifugation (2000 g, 4C, 5 min). The
amount of supernatant spotted on the SDA plate was typically 13 ml. The
plates were incubated at 30C for 1618 hr. The improved mutants were
selected following visual comparison of the inhibition zones. Normally, one
or two improved mutants can be obtained from screening 2000 mutants in
2 weeks.
Site-Directed Mutagenesis
Site-directed mutations were performed using the standard QuikChange
strategy using relevant templates. The primers were ordered from IDT (Inte-
grated DNA Technologies). All mutations were verified by DNA sequencing
(Laragen, Los Angeles, CA).
Saturation Mutagenesis
The LovD G6 gene was randomly mutated at positions of V334 and L361.
Because the two residues are close to each other, the two random mutations
were introduced in a single pair of primers. Two segments were amplified by
PCR and linked together using slice-by-overlap extension (SOE) PCR to give
intact LovD gene, which was subsequently introduced to pET28(a).
Determining Whole-Cell Biocatalysis Activity
Parent LovD G0 and all mutants were cultured in parallel for comparison.
A single colony of the freshly transformed YT2 competent cells was used to
inoculate a 5 ml LB culture supplemented with 35 mg/l kanamycin. Following
overnight growth at 37C, 100 ml culture was inoculated into 50 ml LB mediumlsevier Ltd All rights reserved
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IPTG was added to the cultures and expression of all LovD variants was per-
formed at 25C for 16 hr. To mimic the high density fermentation conditions,
the cells were then concentrated 10-fold before addition of substrates.
A 10 ml aliquot of each culture was collected by centrifugation (4C, 2000 g,
10 min). The cell pellet was gently resuspended in 1 ml medium supernatant,
followed by addition of 70 ml MJA (300 mM stock) to a final concentration of
15 mM. The concentrated culture was then divided into seven 200 ml aliquots
and 1 ml pure DMB-SMMP was added to each sample to a final concentration
of 20 mM. The small cultures were then shaken at 300 rpm at 25C. At each
time point, a complete extraction of one culture aliquot was performed by add-
ing 10 ml 20% SDS for cells lysis, followed by extraction with 500 ml ethyl
acetate containing 1% trifluoroacetic acid (TFA). The organic phase was
removed, evaporated, and redissolved in 500 ml acetonitrile for HPLC analysis.
The whole-cell activity was determined by fitting the linear regions of the
conversion time course plot.
Kinetic Assay of LovD Variants toward MJA and DMB-SMMP
To obtain KM values for MJA and kcat, the DMB-SMMP concentration was
fixed at 2 mM, while the concentration of MJA was varied from 0.25 to
5 mM. To obtain KM values for DMB-SMMP and kcat, the MJA concentration
was fixed at 2 mM, while the concentration of DMB-SMMP was varied from
0.5 to 5 mM. Dimethyl sulfoxide (DMSO) was added to a final concentration
of 10% to facilitate the solubilization of DMB-SMMP. At different time points
of the kinetic assay, an aliquot of the reaction mixture was removed, quenched
with 1% TFA, and extracted with EA containing 1% acetic acid. The organic
phase was separated, dried, resolubilized by acetonitrile (ACN), and analyzed
by a Beckman Gold HPLC using a reverse-phase C18 column (Alltech Apollo
5ı`, 150 mm 3 4.6 mm) and a linear gradient: 60% ACN in water (0.1% TFA) to
95% ACN in water (0.1% TFA) for 10 min, 1 ml/min. Conversion of MJA to SVA
was measured by integration of the peaks at 238 nm.
Kinetic Assay of LovD Variants toward MB-SMMP
To compare the kcat of LovD mutants toward lovastatin synthesis using
MB-SMMP as the substrate, both MJA and MB-SMMP were fixed at 2 mM.
DMSOwas added to a final concentration of 10% to facilitate the solubilization
of MB-SMMP. At different time points of the kinetic assay, an aliquot of the
reaction mixture was removed, quenched with 1% TFA, and extracted with
EA containing 1% acetic acid. The organic phase was separated, dried, reso-
lubilized by ACN, and analyzed HPLC using the same program described
above.
In Vitro Assay of LovD Variants toward LovF
Fifty micromoles of LovF (Xie et al., 2009a) was incubated with 1 mMLovD vari-
ants, 2 mM MJA, 2 mM malonyl-CoA, 2 mM S-(50-adenosyl)-L-methionine
chloride (SAM), 2 mM NADPH in 100 mM phosphate-buffered saline
(pH 7.4). At 1 hr and 2 hr time points, an aliquot of the reaction mixture was
removed, quenched with 1%TFA, and extracted with EA containing 1% acetic
acid. The organic phase was separated, dried, resolubilized by ACN, and
analyzed by HPLC using the same program described above.
Comparing Expression Levels of Soluble LovD
Each expression plasmid encoding LovD mutant was transformed into E. coli
BL21(DE3). The transformant was cultured in 50 ml LB medium containing
35 mg/l kanamycin at 37C to optical density (OD600) value of 0.40.6. Protein
expression was induced with 0.1 mM IPTG and the subsequent expression
was performed at 25C for 16 hr. Cells were collected by centrifugation
(2000 g, 4C, 15 min), resuspended in 7 ml Buffer A (50 mM Tris–HCl
[pH 8.0], 2 mM DTT, 2 mM EDTA), and lysed by sonication. Cell debris and
insoluble proteins were removed by centrifugation (20,000 g, 4C, 1 hr). To
the cleared cell lysate, excess amount (0.5 ml) of Ni-NTA resin (QIAGEN,
Valencia, CA) was added to each sample. The mutants were then purified
using a step gradient of Buffer A with increasing concentration of imidazole
(10, 20, and 250 mM). LovD variants were eluted with 5 ml Buffer A containing
250 mM imidazole. No LovD protein was found in other fractions. The protein
concentrations were qualitatively assessed by SDS-PAGE and quantitatively
determined by the Bradford protein assay using bovine serum albumin as
the standard.Chemistry & Biology 16, 1064–Tm Measurement by Circular Dichroism
Samples were prepared by adding 50 mg proteins to 250 ml 10 mM Tris-HCl
buffer (pH 7.0). The sample was placed in a quartz cuvette with a 1 cm path
length and heated in a Peltier-controlled cell at a rate of 1C per min. Ellipticity
was monitored at 222 nm in a Jasco spectropolarimeter (Jasco Inc., Easton,
MD). The midpoint of the denaturation curve was determined with Microcal
Origin 5.0 software (OriginLab Corporation, Northampton, MA).
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The coordinates and structure factors for G0, SeMet G0, G5, G5-MJA,
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